- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07833176
Comparative Efficacy of Amoxicillin, Metronidazole, and Chlorhexidine in Preventing Alveolar Osteitis
Comparative Efficacy of Amoxicillin, Metronidazole, and Chlorhexidine in Preventing Alveolar Osteitis Following Lower Third Molar Extraction: A Three-Arm Double-Blinded Randomized Controlled Trial
This study will compare the effectiveness of amoxicillin, metronidazole, and chlorhexidine in preventing alveolar osteitis (dry socket) following lower third molar extraction. Participants will be randomly assigned to one of three groups: amoxicillin, metronidazole, or chlorhexidine. Participants will be assessed on Days 3 and 7 after extraction for the presence or absence of alveolar osteitis and postoperative pain. The study will determine whether there is a difference in the incidence of alveolar osteitis among the three treatment groups.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Alveolar osteitis, commonly known as dry socket, is a frequent postoperative complication following lower third molar extraction and may cause significant pain and delayed healing. This study will compare the efficacy of amoxicillin, metronidazole, and chlorhexidine in preventing alveolar osteitis following lower third molar extraction.
This is a three-arm, double-blinded randomized controlled trial to be conducted at the Department of Oral and Maxillofacial Surgery, Khyber College of Dentistry, Peshawar. Patients aged 18-40 years who require extraction of an impacted or partially erupted mandibular third molar under local anesthesia and meet the study eligibility criteria will be considered for participation.
Eligible participants who provide written informed consent will be randomly allocated to one of three groups: Group A will receive amoxicillin, Group B will receive metronidazole, and Group C will receive chlorhexidine as the control intervention. A computer-generated randomization sequence and sequentially numbered, opaque, sealed envelopes will be used for allocation concealment. Placebo tablets and placebo gel will be used to maintain blinding of participants and outcome assessors.
Following extraction, participants will receive standardized postoperative instructions according to their assigned intervention. Participants will be assessed on Days 3 and 7 following extraction. A blinded assessor will evaluate the extraction site for alveolar osteitis using Blum's criteria. The presence or absence of alveolar osteitis will be recorded as a binary outcome. Postoperative pain will also be assessed using a Visual Analogue Scale, and additional postoperative complications or adverse effects will be documented.
The primary objective is to compare the incidence of alveolar osteitis among patients receiving prophylactic amoxicillin, metronidazole, or chlorhexidine following lower third molar extraction. The overall comparison among the three groups will be performed using the Chi-square test, with Fisher's exact test used when appropriate. Planned pairwise comparisons will include amoxicillin versus chlorhexidine, metronidazole versus chlorhexidine, and amoxicillin versus metronidazole, with Bonferroni correction for multiple comparisons.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Dr Sana Mushtaq, BDS, FCPS
- Número de teléfono: +923349249676
- Correo electrónico: sana.mushtaq@kcd.edu.pk
Copia de seguridad de contactos de estudio
- Nombre: Dr Syed Muaz Masoom Shah, BDS, MHR
- Número de teléfono: +923339299120
- Correo electrónico: muazmasoom.shah@kcd.edu.pk
Ubicaciones de estudio
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakistán, 25000
- Reclutamiento
- Khyber College of Dentistry, Peshawar
-
Contacto:
- Syed Sana Mushtaq, BDS, MHR
- Número de teléfono: +92 3349249676
- Correo electrónico: sana.mustaq@kcd.edu.pk
-
Contacto:
- Danish Khan, BDS*
- Número de teléfono: +92 3058603351
- Correo electrónico: danish.khan@kcd.edu.pk
-
Investigador principal:
- Syeda Humera Abdul Mutlaib, BDS*
-
Sub-Investigador:
- Hira Khan, BDS*
-
Sub-Investigador:
- Hira Fayaz, BDS*
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients aged 18 to 40 years.
- Patients requiring non-surgical extraction of impacted or partially erupted mandibular third molars under local anesthesia.
- Patients classified as American Society of Anesthesiologists (ASA) Physical Status I or II.
- Patients who provide written informed consent to participate in the study.
Exclusion Criteria:
- Known allergy or drug hypersensitivity reaction to amoxicillin or metronidazole.
- Patients presenting with active infection at the extraction site, evidenced by pus discharge.
- Periodontally compromised (Grade 1) tooth.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Amoxicillin Group
Participants will receive amoxicillin as the assigned prophylactic intervention following lower third molar extraction. Placebo gel will be provided to maintain double blinding. |
Amoxicillin will be administered as the prophylactic intervention to participants assigned to the amoxicillin group following lower third molar extraction. Placebo gel will be provided to maintain double blinding. |
|
Experimental: Metronidazole Group
Participants will receive metronidazole as the assigned prophylactic intervention following lower third molar extraction. Placebo gel will be provided to maintain double blinding. |
Metronidazole will be administered as the prophylactic intervention to participants assigned to the metronidazole group following lower third molar extraction. Placebo gel will be provided to maintain double blinding. |
|
Comparador activo: Chlorhexidine Control Group
Participants will receive chlorhexidine as the control intervention following lower third molar extraction. Placebo tablets will be provided to maintain double blinding. |
Chlorhexidine will be administered as the control intervention to participants assigned to the chlorhexidine group following lower third molar extraction. Placebo tablets will be provided to maintain double blinding. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of Alveolar Osteitis
Periodo de tiempo: Postoperative Day 3 and Day 7
|
Alveolar osteitis will be assessed as a binary outcome (yes/no) following lower third molar extraction. The incidence of alveolar osteitis will be compared among the amoxicillin, metronidazole, and chlorhexidine groups. |
Postoperative Day 3 and Day 7
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Postoperative Pain
Periodo de tiempo: Postoperative Day 3 and Day 7
|
Postoperative pain will be assessed using a Visual Analog Scale (VAS) with mild level (0-3), moderate level (3-7), and severe level(7-10) of pain following lower third molar extraction. Pain scores will be recorded and compared among the three study groups. |
Postoperative Day 3 and Day 7
|
|
Complications and Adverse Effects
Periodo de tiempo: Postoperative Day 3 and Day 7
|
Complications and adverse effects following lower third molar extraction and administration of the assigned intervention will be assessed and recorded. |
Postoperative Day 3 and Day 7
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Danish Khan, BDS*, Khyber College of dentistry
- Director de estudio: Dr Sana Mushtaq, BDS, FCPS, Khyber College of dentistry
- Investigador principal: Dr Syed Muaz Masoom Shah, BDS, MHR, Khyber College of dentistry
- Investigador principal: Dr Braikhna Murad, BDS, FCPS, Khyber College of dentistry
Publicaciones y enlaces útiles
Publicaciones Generales
- Arteagoitia MI, Barbier L, Santamaria J, Santamaria G, Ramos E. Efficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention of infection and dry socket after third molar extraction. A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2016 Jul 1;21(4):e494-504. doi: 10.4317/medoral.21139.
- Bergdahl M, Hedstrom L. Metronidazole for the prevention of dry socket after removal of partially impacted mandibular third molar: a randomised controlled trial. Br J Oral Maxillofac Surg. 2004 Dec;42(6):555-8. doi: 10.1016/j.bjoms.2004.06.015.
- Wright C, Mistry V, Smyth J, Saik WN, Innes N, Lamont T. The use of chlorhexidine in the prevention of alveolar osteitis after third molar extractions. Evid Based Dent. 2018 Mar 23;19(1):18-19. doi: 10.1038/sj.ebd.6401289.
- Babar A, Ibrahim MW, Baig NJ, Shah I, Amin E. Efficacy of intra-alveolar chlorhexidine gel in reducing frequency of alveolar osteitis in mandibular third molar surgery. J Coll Physicians Surg Pak. 2012 Feb;22(2):91-4.
- Freudenthal N, Sternudd M, Jansson L, Wannfors K. A double-blind randomized study evaluating the effect of intra-alveolar chlorhexidine gel on alveolar osteitis after removal of mandibular third molars. J Oral Maxillofac Surg. 2015 Apr;73(4):600-5. doi: 10.1016/j.joms.2014.08.035. Epub 2014 Sep 16.
- Teshome A. The efficacy of chlorhexidine gel in the prevention of alveolar osteitis after mandibular third molar extraction: a systematic review and meta-analysis. BMC Oral Health. 2017 May 19;17(1):82. doi: 10.1186/s12903-017-0376-3.
- Ramos E, Santamaria J, Santamaria G, Barbier L, Arteagoitia I. Do systemic antibiotics prevent dry socket and infection after third molar extraction? A systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Oct;122(4):403-25. doi: 10.1016/j.oooo.2016.04.016. Epub 2016 May 11.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Dolor
- Manifestaciones neurológicas
- Enfermedades de la Boca
- Enfermedades Estomatognáticas
- Complicaciones Postoperatorias
- Procesos Patológicos
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor Postoperatorio
- Alveolitis seca
- Compuestos de azufre
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Azoles
- Imidazoles
- Amidas
- Biguanides
- Guanidinas
- Amidinos
- Penicilina G
- beta-lactamas
- Lactamas
- Nitroimidazoles
- Compuestos nitro
- Ampicilina
- Penicilinas
- Metronidazol
- Amoxicilina
- Clorhexidina
Otros números de identificación del estudio
- KMU/DIR/CTU/2026/13
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data underlying the results reported in the publication will be made available to qualified researchers upon reasonable request, subject to applicable ethical, institutional, and data protection requirements. The shared data may include de-identified demographic and clinical characteristics, treatment-group allocation, alveolar osteitis outcomes, postoperative pain scores, and recorded complications or adverse effects.
Marco de tiempo para compartir IPD
Data will become available after publication of the study results and will remain available for a period of 5 years.
Criterios de acceso compartido de IPD
Data will be available to qualified researchers for scientifically valid research purposes upon reasonable request. Requests will be reviewed by the study investigators and/or the relevant institutional authority. Data will be provided only after confirmation of appropriate ethical approval and compliance with applicable data protection and confidentiality requirements.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .